Home > Everolimus & Paclitaxel
Everolimus & Paclitaxel
Introducing PROMUS™ Element™ Everolimus-Eluting Coronary Stent System
Two Proven Drug & Polymer Combinations¹ on One Innovative Stent Platform
...With more than 6 million Boston Scientific drug-eluting stents implanted to date²
EVEROLIMUS¹
- Impressive clinical results out to 3 years
- Proven performance with low late loss
- Powerful neointimal suppressor
PLATINUM Global Clinical Program
- Designed to evaluate the safety and effectiveness of the PROMUS™ Element™ Everolimus-Eluting Coronary Stent for the treatment of up two de novo atherosclerotic coronary lesions
- Expected 12 months primary endpoints data release, American College of Cardiology 2011
PACLITAXEL¹
- Proven long-term outcomes out to 5 years
- Robust clinical program with over 50,000 patients studied
- Unique mechanism of action³ with proven subset performance
PERSEUS Global Clinical Program
- Designed to evaluate the safety and effectiveness of the TAXUS™ Element™ Paclitaxel-Eluting Coronary Stent for the treatment of up to two de novo atherosclerotic coronary lesions
- Expected primary endpoints data release, American College of Cardiology 2010
¹ The TAXUS Clinical Program and SPIRIT Clinical Program. SPIRIT is sponsored by Abbott Laboratories group of companies.
² Boston Scientific data on file. Approximately 5 million TAXUS™ Express²™ and TAXUS™ Liberté™ Stents. Approximately 1 million PROMUS™ Stents.
³ Mechanism of action: Patterson et al. ATVB; 2006; 26: 1473-1480. 2. vs. BMS: TAXUS 4-year Meta-analysis (All diabetics), presented by Dr. Stone at TCT 2006. vs. Cypher Stent: TC-WYRE Registry presented by Dr. Kandzari at CRT 2007 and TCT 2006. Kaiser Permanente registry data presented by Dr. Brar at TCT 2006. Prairie Heart Institute registry presented by Dr. Mishkel et al. at TCT 2006. Daemen et al. EuroHeart J. 2007; 28:26-32. 3. TAXUS 4-year Meta-analysis (All diabetics), presented by Dr. Stone at TCT 2006.
Print This Page
This material is not intended for use in the United States and Japan. Stent illustrations not indicative of clinical performance. The TAXUS™ Element™ Drug-Eluting Stent System is CE mark pending, not available for sale in the European Economic Area (EEA). Element™ Bare Metal Stent (BMS) is under development, not available for sale in the European Economic Area (EEA).
All cited trademarks are property of their respective owners. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, precautions and instructions for use can be found in the product labeling with each device. Information for the use only in countries with applicable health authority product registrations.
Please note that access to the following pages, containing certain information, is exclusively reserved for healthcare professionals. More >>